ES2104845T3 - Composiciones lipofilas de sales de antibioticos oligosacaridos. - Google Patents

Composiciones lipofilas de sales de antibioticos oligosacaridos.

Info

Publication number
ES2104845T3
ES2104845T3 ES92309368T ES92309368T ES2104845T3 ES 2104845 T3 ES2104845 T3 ES 2104845T3 ES 92309368 T ES92309368 T ES 92309368T ES 92309368 T ES92309368 T ES 92309368T ES 2104845 T3 ES2104845 T3 ES 2104845T3
Authority
ES
Spain
Prior art keywords
formula
antibiotic
amount
lipophyl
oligosaccharid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92309368T
Other languages
English (en)
Inventor
Mahesh Patel
Vincent P Gullo
Roberta Hare
David Loebenberg
James B Morton
George H Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2104845T3 publication Critical patent/ES2104845T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/08—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
    • C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
    • C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
    • C07H9/04—Cyclic acetals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

Una composición de materia, que comprende: (a) un antibiótico oligosacárido lipófilo representado por la Fórmula I: en la cual: X=NO2, NO,NH2, NHCOCH3, NHOH, NH (C2H5), N(C2H5)2, OHoH; R2=CH3, COCH(CH3)2, COCH3, CO(CH2)3CH3, COCH2CH3 o H; R3=CH3 o H; R4=COCH3, CH(OCH3)(CH3), CH(OH)CH3, CHOoH; R6=CH3 o H; R7= CH3 o H; R8= CH3, CH2OH o H; R9=CH3 o H; Y=OH, H o CH3; W=Cl o H; y Z=Cl o H. (b) al menos aproximadamente una cantidad estequiométrica de una base capaz de formar una sal farmacéuticamente aceptable con un antibiótico oligosacárido lipófilo de Fórmula I; (c) una cantidad de un hidroxipropil--, -o--ciclodextrina en la que el número medio de sustituyentes hidroxipropilo en dicha -, y -ciclodextrina está en el intervalo de aproximadamente 2 a aproximadamente 15, y dicha cantidad es suficiente para conseguir un suministro eficaz de dicho antibiótico oligosacárido lipófilo al suero de un animal, mientras se evita simultáneamente el síndrome de reacción adversa; y (d) 0 a 6,0 % en peso (base, un antibiótico de Fórmula I) de un tensioactivo no iónico farmacéuticamente aceptable.
ES92309368T 1991-10-16 1992-10-14 Composiciones lipofilas de sales de antibioticos oligosacaridos. Expired - Lifetime ES2104845T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77786491A 1991-10-16 1991-10-16

Publications (1)

Publication Number Publication Date
ES2104845T3 true ES2104845T3 (es) 1997-10-16

Family

ID=25111545

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92309368T Expired - Lifetime ES2104845T3 (es) 1991-10-16 1992-10-14 Composiciones lipofilas de sales de antibioticos oligosacaridos.

Country Status (26)

Country Link
US (1) US5624914A (es)
EP (2) EP0610295A1 (es)
JP (1) JP2614407B2 (es)
KR (1) KR100249584B1 (es)
CN (1) CN1035923C (es)
AT (1) ATE156019T1 (es)
AU (1) AU678344B2 (es)
CA (1) CA2121345C (es)
DE (1) DE69221252T2 (es)
DK (1) DK0538011T3 (es)
ES (1) ES2104845T3 (es)
FI (1) FI941723A7 (es)
GR (1) GR3024800T3 (es)
HR (1) HRP921069B1 (es)
HU (1) HUT75157A (es)
IL (1) IL103446A (es)
MX (1) MX9205922A (es)
NO (1) NO307326B1 (es)
NZ (1) NZ244735A (es)
PH (1) PH31675A (es)
PL (1) PL170591B1 (es)
SI (1) SI9200260A (es)
TW (1) TW221378B (es)
WO (1) WO1993007904A1 (es)
YU (1) YU48722B (es)
ZA (1) ZA927923B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948688A (en) * 1991-10-16 1999-09-07 Schering Corporation Method of determining monomeric drug content
US6380172B1 (en) 1991-10-16 2002-04-30 Schering Corporation Monomeric lipophilic oligosaccharide antibiotic compositions
US5652226A (en) * 1995-12-22 1997-07-29 Schering Corporation Water soluble antibiotics
US5776912A (en) * 1996-12-20 1998-07-07 Schering Corporation Lipophilic oligosaccharide antibiotic compositions
US5763600A (en) * 1997-04-18 1998-06-09 Schering Corporation Oligosaccharide antibiotics and process for preparation thereof
ES2245805T3 (es) * 1997-10-03 2006-01-16 Galenica Pharmaceuticals, Inc. Polisacaridos que forman iminas, preparacion de los mismos y el uso de los mismos como adyuvantes de inmunoestimulantes.
US6162910A (en) * 1998-11-30 2000-12-19 Schering Corporation Process for preparing lipophilic oligosaccharide antibiotics
US6320044B1 (en) 1998-12-18 2001-11-20 Schering Corporation Process for recovering lipophilic oligosaccharide antibiotics
PE20001370A1 (es) * 1998-12-18 2000-12-09 Schering Corp Proceso para recuperar antibioticos oligosacaridos lipofilicos
WO2001039573A2 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chemische Fabrik Gmbh Verwendung von lungensurfactant zur behandlung von legionärskrankheit
US6861513B2 (en) 2000-01-12 2005-03-01 Schering Corporation Everninomicin biosynthetic genes
JP4870314B2 (ja) * 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
WO2002032459A2 (en) * 2000-10-17 2002-04-25 Massachusetts Institute Of Technology Method of increasing the efficacy of antibiotics by complexing with cyclodextrins
DE10109166A1 (de) * 2001-02-25 2002-09-12 Combinature Biopharm Ag Avilamycin-Derivate
EP1730163A4 (en) * 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
US7819377B2 (en) * 2004-12-01 2010-10-26 Nitto Denko Corporation Foam filling member
EP1868613B1 (en) * 2005-04-12 2012-03-07 Myrexis, Inc. Polymorphs of 3-o-(3',3'-dimethylsuccinyl) betulinic acid di-n-methyl-d-glucamine
HUE037932T2 (hu) * 2007-09-14 2018-09-28 Sanofi Pasteur Biologics Llc Clostridium difficile A és B toxoidjait tartalmazó gyógyászati kompozíciók
JP2010095454A (ja) * 2008-10-14 2010-04-30 Cyclochem:Kk 抗菌組成物
CA2824800A1 (en) * 2011-01-14 2012-07-19 Emory University Oligosaccharide conjugates for targeting bacteria and uses related thereto
CA2988529A1 (en) 2015-06-10 2016-12-15 Vtesse, Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
CN106317143B (zh) * 2016-08-23 2020-10-30 河北圣雪大成制药有限责任公司 一种提取阿维拉霉素的方法
WO2023156966A1 (en) 2022-02-18 2023-08-24 Beren Therapeutics P.B.C. Compositions of hydroxypropyl-beta-cyclodextrin and methods of purifying the same
CN117024611B (zh) * 2023-03-01 2024-05-17 中国科学院南海海洋研究所 寡糖类抗生素everninomicin高产菌株的构建及活性的应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR128F (es) * 1962-04-02
US3915956A (en) * 1973-07-09 1975-10-28 Schering Corp Reduction products of everninomicins and methods for their manufacture
US3920629A (en) * 1973-09-19 1975-11-18 Schering Corp Desevernitrose everninomicins and method for their manufacture
US4006225A (en) * 1973-10-31 1977-02-01 Schering Corporation Method of using reduction products of everninomicins as antibacterial agents and pharmaceutical compositions useful therefor
US3998708A (en) * 1976-01-19 1976-12-21 Schering Corporation Electrochemical process for preparing hydroxylaminoeverninomicins
US4027016A (en) * 1976-01-19 1977-05-31 Schering Corporation Everninomicin antibacterial derivatives, electrochemical method for their manufacture, method for their use as antibacterial agents, and pharmaceutical compositions useful therefor
US4129720A (en) * 1977-02-14 1978-12-12 Schering Corporation Aminoeverninomicin and derivatives thereof
US4597968A (en) * 1982-08-06 1986-07-01 Schering Corporation Antibiotic 13-384 complex from Micromonospora carbonacea var africana
DE3346123A1 (de) * 1983-12-21 1985-06-27 Janssen Pharmaceutica, N.V., Beerse Pharmazeutische praeparate von in wasser schwerloeslichen oder instabilen arzneistoffen und verfahren zu ihrer herstellung
US4596795A (en) * 1984-04-25 1986-06-24 The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4727064A (en) * 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4735903A (en) * 1984-06-21 1988-04-05 Schering Corporation Micromonospora carbonacea var africana
US4870060A (en) * 1985-03-15 1989-09-26 Janssen Pharmaceutica Derivatives of γ-cylodextrin
US4767748A (en) * 1985-10-15 1988-07-30 Schering Corporation Substituted oligosaccharide antibodies
US4622314A (en) * 1985-10-15 1986-11-11 Schering Corporation Substituted oligosaccharide antibiotics
US5017566A (en) * 1987-12-30 1991-05-21 University Of Florida Redox systems for brain-targeted drug delivery
US5002935A (en) * 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도

Also Published As

Publication number Publication date
HRP921069A2 (en) 1994-12-31
EP0538011A1 (en) 1993-04-21
PL170591B1 (pl) 1997-01-31
YU92192A (sr) 1996-01-09
AU2780692A (en) 1993-05-21
DE69221252T2 (de) 1998-01-22
FI941723A0 (fi) 1994-04-14
EP0538011B1 (en) 1997-07-30
AU678344B2 (en) 1997-05-29
MX9205922A (es) 1994-08-31
JP2614407B2 (ja) 1997-05-28
CA2121345C (en) 1998-08-25
NO941276L (no) 1994-04-08
HUT75157A (en) 1997-04-28
JPH06510546A (ja) 1994-11-24
HK1001085A1 (en) 1998-05-22
IL103446A0 (en) 1993-03-15
CN1073359A (zh) 1993-06-23
SI9200260A (en) 1993-06-30
EP0610295A1 (en) 1994-08-17
US5624914A (en) 1997-04-29
ATE156019T1 (de) 1997-08-15
GR3024800T3 (en) 1998-01-30
CA2121345A1 (en) 1993-04-29
NO307326B1 (no) 2000-03-20
TW221378B (es) 1994-03-01
DE69221252D1 (de) 1997-09-04
DK0538011T3 (da) 1997-09-08
FI941723A7 (fi) 1994-04-14
KR100249584B1 (ko) 2000-04-01
PH31675A (en) 1999-01-18
NO941276D0 (no) 1994-04-08
ZA927923B (en) 1993-04-26
CN1035923C (zh) 1997-09-24
IL103446A (en) 1997-02-18
WO1993007904A1 (en) 1993-04-29
YU48722B (sh) 1999-07-28
HU9401104D0 (en) 1994-07-28
HRP921069B1 (en) 1999-12-31
NZ244735A (en) 1995-12-21

Similar Documents

Publication Publication Date Title
ES2104845T3 (es) Composiciones lipofilas de sales de antibioticos oligosacaridos.
FI950166A0 (fi) Uudet farmaseuttiset koostumukset
CA2221190A1 (en) Novel substituted taxanes and pharmaceutical compositions containing them
ATE55900T1 (de) Feste pharmazeutische formulierungen mit ueber einen weiten bereich variablen langsamen freigabe nullter ordnung durch kontrollierte oberflaechenerosion.
GB1107093A (en) Phenyl aliphatic acids and their salts and esters
MX9207169A (es) Composiciones orales para suprimir olores bucales.
ES2036580T3 (es) Composiciones quimicas y su uso como aditivos a combustibles.
ITTO910939A1 (it) Derivato di alfa-ossoacetammide.
AR008540A1 (es) Composiciones antibioticas de oligosacaridos lipofilicos, composiciones farmaceuticas que los contienen y el uso de dichas composiciones para prepararmedicamentos.
AR019190A1 (es) Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
SE8204918L (sv) Nya 3-amino-pregn-5-en-derivat, deras salter, sett for framstellning och anvendning derav som lekemedel och kompositioner innehallande dem
JPS5492951A (en) Novel aminoglycoside derivative
AR008234A1 (es) Derivados de benzamidas, procedimiento para su preparacion, composiciones farmaceuticas y su uso para la preparacion de un medicamento
AU624951B2 (en) New sulfonamides derived from benzocyclic or benzoheterocyclic acids, their preparation and application in thereapeutics
FI930974A0 (fi) Substituerade aminofosfonatderivat, foerfarande foer framstaellning av desamma och farmaceutiska kompositioner innehaollande desamma
ATE114965T1 (de) Belaghemmende zahnpaste.
AR052853A1 (es) Composiciones orales que contienen compuestos antibacterianos de bifenol
ES2108240T3 (es) Derivados de tiosemicarbazona de 2-formilpiridina, su preparacion y su uso como agentes antitumor.
RU97107153A (ru) Производные колхицина и их терапевтическое применение
CA2322865A1 (en) Pharmaceutical compositions for ulcer
AR026726A1 (es) Nuevos compuestos antitromboticos y composiciones farmaceuticas que los contienen
RU99102690A (ru) Композиции синтетического мыльного бруса с улучшенной способностью к обработке, содержащие амфотерные поверхностно-активные вещества, основанные на минимальных количествах мыла жирной кислоты и минимальных отношениях мыла насыщенной кислоты к мылу ненасыщенной кислоты
AR010377A1 (es) Composiciones farmaceuticas para secar por congelacion que contienen compuestos de nucleosidos, procedimiento para su preparacion y uso de dichas composiciones para fabricar medicamentos.
KR910700230A (ko) 신규 히드록실아민 유도체
CO4771112A1 (es) Pasta/barra de platos transparente

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 538011

Country of ref document: ES